Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,695 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asthma (Diagnosis) Clear all
Completed No phase listed Observational Accepts healthy volunteers

The Role of Epigenetics in Inner City Asthma

NCT01382836
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
6
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 14, 2026, 10:36 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

NCT00124709
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Corticosteroid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Months
Enrollment
1,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study

NCT00346398
View directory record Official record
Conditions
Asthma, Allergic Sensitization
Interventions
Oral mucosal immunoprophylaxis (OMIP), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 30 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 2 Interventional

Study in Patients With Asthma

NCT00215397
View directory record Official record
Conditions
Asthma
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
5 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
3
States / cities
Long Beach, California • Denver, Colorado • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 14, 2026, 10:36 AM EDT
Completed No phase listed Observational

T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma

NCT00001908
View directory record Official record
Conditions
Asthma, Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 3 Interventional

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073840
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
54
States / cities
Oxford, Alabama • Tucson, Arizona • Corona, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

NCT00603278
View directory record Official record
Conditions
Asthma
Interventions
GW685698X, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Not applicable Interventional

Pilot of Exercise and Asthma Control

NCT06651385
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Remote digital therapeutic exercise program
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 14, 2026, 10:36 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Randomized Controlled Trial of Silymarin in Asthma

NCT01049178
View directory record Official record
Conditions
Atopic Asthma
Interventions
Oral Silymarin, Oral Silymarin, maintenance dose, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 3 Interventional

Long-Term Safety Performance of Fexofenadine in Asthma

NCT00045955
View directory record Official record
Conditions
Asthma
Interventions
Fexofenadine, Comparator = Montelukast
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 14, 2026, 10:36 AM EDT
Recruiting Phase 1 Interventional

A Study of CDX-622 in Participants With Mild to Moderate Asthma

NCT07330778
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
CDX-622
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
San Francisco, California • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Not applicable Interventional Results available

Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform

NCT04868500
View directory record Official record
Conditions
Asthma
Interventions
AMAZE™ Application, AMAZE™ Dashboard
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

NCT06531811
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 14, 2026, 10:36 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Not applicable Interventional Results available

Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB)

NCT06336681
View directory record Official record
Conditions
Exercise Induced Bronchospasm, Exercise Induced Asthma
Interventions
PrO2Fit Device
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 14, 2026, 10:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma

NCT07500532
View directory record Official record
Conditions
Acute Otitis Media (AOM), Strep Pharyngitis, Asthma Exacerbation, Pediatric Asthma
Interventions
Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis, Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation, Routine Asthma Management (in-person and telehealth visits)- Control Group, Routine ENT Management (in-person and telehealth visits)- Control Group
Device · Other
Lead sponsor
Medentum Innovations
Industry
Eligibility
3 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tuscon, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Not applicable Interventional

Asthma and Obstructive Sleep Apnea (OSA)

NCT01026298
View directory record Official record
Conditions
Asthma, Obstructive Sleep Apnea
Interventions
FDA-Approved Treatment
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 73 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 14, 2026, 10:36 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Molekule for Allergic Rhinitis/Asthma

NCT03627689
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Active air purifier in respiratory allergies/asthma, Sham air purifier
Other
Lead sponsor
Molekule
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Not applicable Interventional

Assessing the Use of Mobile Technology in Adult Asthma Patients

NCT03103880
View directory record Official record
Conditions
Asthma
Interventions
BreatheSmart
Device
Lead sponsor
CoheroHealth
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 14, 2026, 10:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluate Pharmacokinetics and Safety of Slow Release DHEA

NCT05623059
View directory record Official record
Conditions
Asthma, Genotype
Interventions
Slow Release DHEA
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 10:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Severe Asthma Research Program

NCT01606826
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years and older
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 10:36 AM EDT
Completed No phase listed Observational Results available

Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents

NCT04748055
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 21 Years
Enrollment
40 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 10:36 AM EDT
Terminated Phase 4 Interventional

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

NCT00486343
View directory record Official record
Conditions
Asthma
Interventions
Zileuton CR, Placebo
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 14, 2026, 10:36 AM EDT